...
首页> 外文期刊>Thyroid: official journal of the American Thyroid Association >Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
【24h】

Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.

机译:患有或未患有促甲状腺激素受体抗体(由猪甲状腺细胞决定)的未治疗Graves患者的免疫球蛋白普遍在培养的人甲状腺滤泡中引起有效的甲状腺激素释放活性。

获取原文
获取原文并翻译 | 示例
           

摘要

Thyrotropin receptor antibody (TRAb), comprising thyrotropin binding inhibitor immunoglobulin (TBII) and thyroid-stimulating antibody (TSAb), both of which are conventionally determined using porcine thyrocytes in Japan, is not always positive in patients with untreated Graves' disease. To elucidate whether immunoglobulin G (IgG) obtained from TBII/TSAb-positive (+) or negative (-) Graves' disease patients are responsible for hyperthyroidism, we investigated the thyroid hormone-releasing activity (THRA) of these IgGs in human thyroid follicles in suspension culture, in which bovine thyrotropin (bTSH) is detectable even at 0.1 microU/mL. Human thyroid follicles, obtained from Graves' disease patients by subtotal thyroidectomy, were cultured in serum-free F-12/RPMI-1640 medium supplemented with bTSH or purified Graves' IgGs. After preculturing for 3 days, 125I was added, and after an additional 3 days of culture, 1251 incorporated into the thyroid follicles and organic 125I released into the culture medium (mainly 1251 -T4 + 125I-T3) were counted. Seventy TBII(+)/TSAb( + )-, 3 TBII( + )/TSAb( - )-, and 3 TBII( - )/TSAb( + )- patients with untreated Graves' disease were all positive for THRA, which became undetectable in spontaneous remission obtained after several years of medical treatment. The THRA was equivalent to 0.8-230 microU/mL bTSH. Furthermore, 2 TBII(-)/TSAb(-) patients were significantly positive for THRA. This TBII(-)/TSAb(-)IgG stimulated human thyrocytes to produce cyclic adenosine monophosphate (cAMP), and this was partially inhibited by antihuman IgG antibody. The THRA induced by TBII(+)/TSAb(+) IgGs as well as TBII(-)/TSAb(-) IgG was inhibited by blocking-type TRAb obtained from TBII(+) patients with myxedema. There was a significant correlation between THRA and TSAb. These in vitro findings suggest that all IgGs obtained from untreated Graves' patients (n = 78) elicit potent THRA in human thyroid follicles in suspension culture. Because the TBII(-)/TSAb(-) IgGs can stimulate cAMP production in human but not in porcine thyrocytes, they probably recognize epitope(s) of TSH-binding sites specific to the human thyrotropin (hTSH) receptor. Furthermore, we have demonstrated that the thyroid gland of hyperthyroid Graves' patients is stimulated by IgG(s) equivalent to at least 0.8 microU/mL bTSH (about 5 microU/mL hTSH) in vitro.
机译:甲状腺素结合受体免疫球蛋白(TBII)和甲状腺刺激性抗体(TSAb)都由日本传统上使用猪甲状腺细胞测定,促甲状腺素受体抗体(TRAb)在未治疗的Graves病患者中并不总是呈阳性。为了阐明从TBII / TSAb阳性(+)或阴性(-)Graves病患者获得的免疫球蛋白G(IgG)是导致甲亢的原因,我们调查了这些IgG在人甲状腺滤泡中的甲状腺激素释放活性(THRA)。在悬浮培养中,甚至在0.1 microU / mL时也可检测到牛促甲状腺激素(bTSH)。通过甲状腺全切除术从格雷夫斯病患者那里获得的人甲状腺滤泡,在无血清的F-12 / RPMI-1640培养基中培养,该培养基补充了bTSH或纯化的格雷夫斯IgG。预培养3天后,加入125I,再培养3天后,计数掺入甲状腺滤泡中的1251和释放到培养基中的有机125I(主要是1251-T4 + 125I-T3)。 Graves病未经治疗的70例TBII(+)/ TSAb(+)-,3 TBII(+)/ TSAb(-)-和3 TBII(-)/ TSAb(+)-患者的THRA均呈阳性。经过数年的治疗后无法自发缓解。 THRA相当于0.8-230 microU / mL bTSH。此外,有2名TBII(-)/ TSAb(-)患者的THRA阳性。此TBII(-)/ TSAb(-)IgG刺激人的甲状腺细胞产生环状单磷酸腺苷(cAMP),并且被抗人IgG抗体部分抑制。 TBII(+)/ TSAb(+)IgG以及TBII(-)/ TSAb(-)IgG诱导的THRA被粘液型TBII(+)患者获得的阻断型TRAb抑制。 THRA和TSAb之间存在显着相关性。这些体外发现表明,在悬浮培养中,从未治疗的Graves病患(n = 78)获得的所有IgG均可在人甲状腺滤泡中产生有效的THRA。由于TBII(-)/ TSAb(-)IgG可以刺激人的cAMP产生,但不能刺激猪的甲状腺细胞,因此它们可能识别人促甲状腺激素(hTSH)受体特异的TSH结合位点的表位。此外,我们已经证明,在体外,相当于至少0.8 microU / mL bTSH(约5 microU / mL hTSH)的IgG刺激甲状腺功能亢进Graves患者的甲状腺。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号